Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 11/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.67 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | GC | P02774 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | RXRA | P19793 | 1/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lexacalcitol SCHEMBL5617343 | 1.00 | VDR (0.83) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Lexacalcitol SCHEMBL5617341 | 1.00 | VDR (0.83) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Lexacalcitol SCHEMBL24066829 | 1.00 | VDR (0.83) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL30956326 | 0.95 | VDR (0.85) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL9754276 | 0.92 | VDR (0.91) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL9754278 | 0.92 | VDR (0.91) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL14027728 | 0.92 | VDR (0.80) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL6256864 | 0.91 | VDR (0.72) | VDRMAPTADORA3SLC6A2AGTR1 | |
| SCHEMBL12516472 | 0.90 | VDR (0.77) | VDRMAPTADORA3ABCB11PGR | |
| SCHEMBL20115744 | 0.90 | VDR (0.77) | VDRMAPTADORA3ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260028400-A1 | ANTI-ROR1 ANTIBODY AND USE THEREOF | AIMED BIO INC (KR) | 2026-01-29 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250270320-A1 | ANTI-PD-1 ANTIBODY AND USES THEREOF | EUTILEX CO., LTD. (KR) | 2025-08-28 | — | — | US | claimed |
| WO-2025122699-A1 | CDC7 INHIBITOR COMBINATIONAL THERAPY | Lin Bioscience, Inc. (TW) | 2025-06-12 | — | — | WO | claimed |
| EP-4563597-A1 | ANTI-ROR1 ANTIBODY AND USE THEREOF | AIMED BIO INC. (KR) | 2025-06-04 | — | — | EP | claimed |
| WO-2025111447-A1 | TREATMENT OF CANCER WITH DRUG COMBINATIONS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2007036802-A2 | SUBLINGUAL DOSAGE FORM COMRISING VITAMIN D ANALOGUE, IN PARTICULAR CALCITRIOL | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (GB) | 2007-04-05 | — | — | WO | claimed |
| EP-1748784-A2 | INDUCTION OF INNATE IMMUNITY BY VITAMIN D3 AND ITS ANALOGS | Cedars-Sinai Medical Center (US) | 2007-02-07 | — | — | EP | claimed |
| WO-2005115403-A2 | INDUCTION OF INNATE IMMUNITY BY VITAMIN D3 AND ITS ANALOGS | CEDARS-SINAI MEDICAL CENTER (US) | 2005-12-08 | — | — | WO | claimed |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | US | claimed |
| US-20040024044-A1 | Exemestane as chemopreventing agent | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-05 | — | — | US | claimed |
| EP-1377298-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1317270-A1 | EXEMESTANE FOR THE TREATMENT OF OESTROGEN-DEPENDENT CANCERS | Pharmacia Italia S.p.A. (IT) | 2003-06-11 | — | — | EP | claimed |
| WO-2002072106-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS WITH EXEMESTANE | PHARMACIA ITALIA SPA (IT) | 2002-09-19 | — | — | WO | claimed |
| WO-2002020020-A1 | EXEMESTANE AS CHEMOPREVENTING AGENT | PHARMACIA ITALIA S.P.A. (IT) | 2002-03-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | VDR 3577/4885MAPT 778/4885ADORA3 2375/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | VDR 2627/4885MAPT 1889/4885ADORA3 4679/4885 |
| US-20260028400-A1 | ANTI-ROR1 ANTIBODY AND USE THEREOF | RORB, RORC, RORA | VDR 571/4885MAPT 1814/4885ADORA3 1894/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | VDR 1706/4885MAPT 4363/4885ADORA3 1819/4885 |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | CYP19A1, BRCA1, ESR2 | VDR 916/4885MAPT 4675/4885ADORA3 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.